MEDlight 4557, Руководство пользователя и техническое описание, Страница: 20 / 30

U
SER
M
ANUAL
& T
ECHNICAL
D
ESCRIPTION
N-LINEpro_User Manual_2018-09-20.doc MEDlight GmbH
Werrestr. 94
32049 Herford
Germany Phone: +49 5221 99429-0
Fax: +49 5221 99429-40
e-mail: info@medlight.eu
www.medlight.eu
Page 20 of 30

Accompanying medication with the potential of causing skin damage or increasing
photosensitivity
Source: Prof. Dr. E. Hölze, et Al. ‚Empfehlungen zur Phototherapie und Photochemotherapie‘ DDG Berlin 2009
6 SIDE EFFECTS
6.1 UVB – Side Effects
The most common acute side effects include sunburn-like erythema after UVB irradiation.
Without eye protection acute conjunctivitis and keratitis may occur.
After UVB phototherapy, however, no reliable increase in the risk for basal cell carcinoma
was so far observed. Recent works confirm this also for the narrowband-spectrum
application in contrast to theoretical considerations that want to ascribe a 50% risk increase for
carcinoma to the narrowband spectrum UVB therapy.
Side Effect UVB
Erythema if overdosed ++
Phototoxic reaction due to unintentional intake of a photosensitizer ±
Conjunctivitis and keratitis (if no eye protection is used) ++
Provocation of photodermatoses +
UV-Lentigines +
Photoaging of the skin ++
Actinic keratoses and squamous-cell carcinoma +
Melanoma ?
++ high risk + moderate risk ± low risk ? in principle possible, but no data available
Source: Prof. Dr. E. Hölze, et Al. ‚Empfehlungen zur Phototherapie und Photochemotherapie‘ DDG Berlin 2009
6.2 UVA – Side Effects
The most common acute side effects are phototoxic reactions due to an overdose
irradiation in the context of photochemotherapy. Without eye protection acute
conjunctivitis, keratitis and for UVA or PUVA treatment a chronic cataract may occur. The
provocation of photodermatoses, mainly polymorphic light eruption, is possible, particularly
in the higher dosed UVA therapy. If inadvertently phototoxic substances or drugs are supplied externally
or systemically, excessive phototoxic skin reactions may occur, especially in UVA treatments or
photochemotherapy.
Occasionally, a PUVA-itching may occur, which can therapeutically hardly be influenced, and sometimes
leads to the discontinuation of the therapy. Rarely, acral blisters appear during PUVA treatment due to a
loosening of the dermo-epidermal border zone with strong mechanical stress. The potential systemic
toxicity of the photochemotherapy encompasses nausea after the tablet intake and occasional